By Adam Jourdan

A Chinese anti-monopoly team visited medical devices and semiconductor firms in Shanghai at the start of September, the country's Ministry of Commerce said in a statement on Thursday, without making clear the purpose of the visit.

"Through onsite visits to firms and by holding forums, we deepened our understanding of the competitive environment in industries such as semi-conductors and medical devices," the ministry said in the statement published on its website.

China is looking to consolidate some key sectors from healthcare to dairy to increase the ability of local firms to compete against foreign rivals.

The three-day visit was led by the Zheng Wen, the deputy head of the Ministry of Commerce's anti-monopoly unit. The ministry focuses on the regulation of mergers and acquisitions (M&A), rather than violations of China's anti-monopoly law.

Industry insiders expect a wave of M&A in the domestic medical devices sector. Beijing is looking to promote local players in the market which is says will reduce soaring healthcare costs, a potential threat to the global firms who currently dominate the sector.

China has also been looking to consolidate the semiconductor market in order to make the domestic industry more competitive, analysts said.

Some foreign companies have become concerned they are being targeted by Chinese regulators, a U.S. business lobby said this week, as a Chinese antitrust agency defended probes into firms such as U.S. chipmaker Qualcomm Inc.

 

Related Articles

Qualcomm faces China bribery allegations from U.S. regulator

by Reuters |

Leading mobile chipmaker Qualcomm said on Wednesday it could face a civil action from U.S. authorities over alleged bribery of officials associated with state-owned companies in China.

Marubeni says Chinese authorities detain three staff at grain unit

by Reuters |

Three employees at one of Marubeni Corp's grain trading units in China have been detained by authorities, the Japanese trading house said on Thursday, a move sources told Reuters was prompted by allegations the unit evaded taxes on soy bean imports.

GSK case a 'warning' to all foreign firms in China

by Reuters |

Corruption charges against GlaxoSmithKline Plc executives in China are a warning to other foreign firms and could do irreparable damage to the British drugmaker's Chinese operations, the official Xinhua news agency said on Friday.